In the Claims

1.-64. (Cancelled)

65. (Currently Amended) A process for treating fibroses comprising administering a therapeutically effective amount of a pharmaceutical composition comprising at least one biocompatible polymer ~~selected from the group consisting of RGTA 1112 (CM_2DPheS_2) and RGTA 1113 (CM_3DTyrS_2)~~ having the general formula (I):

$A_aX_xY_yZ_z$,

wherein:

A is a glucose monomer;

X is COOH or COONa;

Y is SO_3H or SO_3^-;

Z is a tyrosine or phenylalanine residue optionally substituted with Y, wherein Z is linked to the glucose monomer via $-CH_2C(=O)-$;

$_a$ represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 Da;

$_x$ represents the percentage of glucose monomers A that bear a X group, and $_x$ is statistically about 28.9% when Z is Phe, and statistically about 19.8% when Z is Tyr,

$_y$ represents the percentage of glucose monomers A that bear a Y group, and $_y$ is statistically about 56.2% when Z is Phe, and statistically about 65.9% when Z is Tyr, and

$_z$ represents the percentage of glucose monomers A by the groups Z, and $_z$ is statistically about 17.9% when Z is Phe, and about 28.9% when Z is Tyr.

66.-68. (Cancelled)

69. (New) The process of Claim 65 where

$_x$ is 28.9% when Z is Phe and is 19.8% when Z is Tyr;

$_y$ is 56.2% when Z is Phe and is 65.9% when Z is Tyr; and

$_z$ is 17.9% when Z is Phe and about 28.9% when Z is Tyr.